Rafael Bravo

Rafael Bravo serves as the Vice President of Global Medical Affairs at Novo Nordisk, leading the Obesity Global Medical Affairs team since March 2018. In this role, Rafael is responsible for managing the company's GLP-1 based obesity portfolio, including Semaglutide and Liraglutide, alongside business development assets such as Inversago. Prior to this position, Rafael held various leadership roles, including Medical Director for Mexico at Novo Nordisk, Novartis, and Janssen, focusing on clinical development, regulatory affairs, and pharmacovigilance. Rafael's medical education includes fellowships and residencies in Endocrinology, Diabetes, and Internal Medicine from prestigious institutions such as Beth Israel Medical Center and Mount Sinai Medical Center.